Lidocaine Laboratoire Aguettant

Lidocaine, the active ingredient in Lidocaine Laboratoire Aguettant, is a local anesthetic presented as a sterile solution for infiltration, intradermal, and intravenous use. It provides reversible loss of sensation for minor surgical, dental, and cardiac procedures. GNH USA supplies Lidocaine Laboratoire Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic that blocks nerve conduction in various clinical settings. - Minor surgical procedures: provides rapid, reversible numbness of the targeted area. - Dental procedures: enables pain‑free tooth extractions and restorative work. - Nerve block anesthesia: facilitates regional anesthesia for limb or trunk surgeries. - Intravenous antiarrhythmic therapy: assists in managing certain cardiac arrhythmias.

Lidocaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Burning or stinging at the injection site - Transient dizziness or light‑headedness - Nausea or mild gastrointestinal upset - Headache - Metallic taste in the mouth - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Cardiac arrhythmias, including ventricular tachycardia - Central nervous system toxicity leading to seizures - Methemoglobinemia - Respiratory depression or apnea

When using lidocaine, consider the following safety measures. - Assess allergy history: verify no known hypersensitivity to amide‑type local anesthetics. - Use caution in cardiac patients: monitor ECG in individuals with conduction disorders. - Avoid excessive dosing: adhere to recommended maximum dose limits. - Adjust for hepatic impairment: consider reduced clearance in liver disease. - Pregnancy and lactation: use only if the clinical benefit outweighs potential risk. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with several drug classes; awareness helps prevent toxicity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine) – increase lidocaine plasma levels. - Beta‑blockers – may potentiate cardiac depression. - Strong CYP3A4 inhibitors (e.g., erythromycin) – raise systemic exposure. - MAO inhibitors – elevate risk of arrhythmias. - General anesthetics (e.g., propofol) – enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Concurrent local anesthetics – additive toxicity risk. - Diuretics – may alter lidocaine distribution. - Anticonvulsants – could lower seizure threshold. - Calcium channel blockers – may affect cardiac conduction when combined.